CIA
GILD icon

Cladis Investment Advisory’s Gilead Sciences GILD Stock Holding History

Cladis Investment Advisory’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,500
Closed -$268K – 137
2022
Q1 		$268K Sell
4,500
-1,200
-21% -$76.7K 0.22% 118
2021
Q4 		$414K Buy
+5,700
New +$393K 0.33% 89

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cladis Investment Advisory's GILD Position: Q2 2022 in Review

Cladis Investment Advisory sold out of Gilead Sciences (GILD) in Q2 2022, closing a stake of 4,500 shares — an estimated $268K sold.

Cladis Investment Advisory first reported a position in GILD in Q4 2021 and held it in 2 quarters. The position peaked at $414K in Q4 2021. 1,603 funds tracked by Wall St. Rank hold GILD as of Q2 2022.

  • Cladis Investment Advisory reported no remaining Gilead Sciences position as of Q2 2022 after selling out during the quarter.
  • Cladis Investment Advisory sold 4,500 Gilead Sciences shares in Q2 2022, an estimated $268K.
  • Cladis Investment Advisory first reported a position in Gilead Sciences in Q4 2021 and held it in 2 quarters.
  • Cladis Investment Advisory's Gilead Sciences position peaked at $414K in Q4 2021.
  • 1,603 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2022.

Based on Cladis Investment Advisory's 13F filing for Q2 2022, filed 9 Aug 2022.